53 related articles for article (PubMed ID: 90738)
1. [Assay of "pregnancy alpha 2 glycoprotein" in the serum of prostatic cancer patients and changes during estrogen therapy].
Lanson Y; Lanson M; Gutman N; Muh JP
J Urol Nephrol (Paris); 1979 Jun; 85(6):399-407. PubMed ID: 90738
[TBL] [Abstract][Full Text] [Related]
2. Significance of pregnancy-associated alpha 2-glycoprotein (alpha 2-PAG) in patients with breast, gastric and colorectal cancer.
Shimizu Y; Oshima K; Nakano Y; Fujita M; Taguchi T
Biken J; 1981 Sep; 24(3):95-102. PubMed ID: 6175310
[TBL] [Abstract][Full Text] [Related]
3. Demonstration of alpha 2-pregnancy associated-glycoprotein (alpha 2-PGA) in serum of men with different localization of cancer.
Porr PJ; Abrudan O; Dejica D
Neoplasma; 1979; 26(3):325-8. PubMed ID: 93708
[TBL] [Abstract][Full Text] [Related]
4. [Acute phase proteins in the diagnosis of prostatic neoplasms].
Nikolaev AA; Afanas'eva AV; Antonov NM; Gracheva LN; Nikulina DM
Lab Delo; 1981; (4):230-2. PubMed ID: 6164861
[No Abstract] [Full Text] [Related]
5. Serum insulin level, disease stage, prostate specific antigen (PSA) and Gleason score in prostate cancer.
Lehrer S; Diamond EJ; Stagger S; Stone NN; Stock RG
Br J Cancer; 2002 Sep; 87(7):726-8. PubMed ID: 12232754
[TBL] [Abstract][Full Text] [Related]
6. Whole blood selenium levels (WBSL) in patients with prostate cancer (PC), benign prostatic hyperplasia (BPH) and healthy male inhabitants (HMI) and prostatic tissue selenium levels (PTSL) in patients with PC and BPH.
Muecke R; Klotz T; Giedl J; Buentzel J; Kundt G; Kisters K; Prott FJ; Micke O
Acta Oncol; 2009; 48(3):452-6. PubMed ID: 18855158
[TBL] [Abstract][Full Text] [Related]
7. Ethinylestradiol and diethylstilbestrol induced antibodies and vascular thrombosis.
Beaumont V; Lemort N; Abbou CC; Beaumont JL
Biomedicine; 1980 Feb; 32(1):26-31. PubMed ID: 7370379
[TBL] [Abstract][Full Text] [Related]
8. Pretreatment serum level of HER2/nue as a prognostic factor in metastatic prostate cancer patients about to undergo endocrine therapy.
Okegawa T; Kinjo M; Nutahara K; Higashihara E
Int J Urol; 2006 Sep; 13(9):1197-201. PubMed ID: 16984552
[TBL] [Abstract][Full Text] [Related]
9. Serum active hepatocyte growth factor (AHGF) in benign prostatic disease and prostate cancer.
Yasuda K; Nagakawa O; Akashi T; Fujiuchi Y; Koizumi K; Komiya A; Saiki I; Fuse H
Prostate; 2009 Mar; 69(4):346-51. PubMed ID: 19021204
[TBL] [Abstract][Full Text] [Related]
10. [Inhibition of the free, biologically active testosterone level by Turisteron in patients with prostate cancer].
Stahl F; Schnorr D; Rohde W; Dörner G
Z Urol Nephrol; 1987 Mar; 80(3):135-8. PubMed ID: 3604472
[TBL] [Abstract][Full Text] [Related]
11. [Effect of estrogen treatment on antithrombin III activity in patients with carcinoma of the prostate].
Hayashi T; Takenawa J; Ryoji O; Hiura M; Taki Y; Kiriyama T
Hinyokika Kiyo; 1989 May; 35(5):807-13. PubMed ID: 2478002
[TBL] [Abstract][Full Text] [Related]
12. Role of surface negative charge in platelet function related to the hyperreactive state in estrogen-treated prostatic carcinoma.
Jung SM; Kinoshita K; Tanoue K; Isohisa I; Yamazaki H
Thromb Haemost; 1982 Jun; 47(3):203-9. PubMed ID: 6180496
[TBL] [Abstract][Full Text] [Related]
13. Serial measurements of tissue polypeptide specific antigen (TPS), PSA, PAP and CEA serotest values in treated patients with primary and metastatic prostate cancer.
Tarle M
Anticancer Res; 1993; 13(3):769-77. PubMed ID: 7686362
[TBL] [Abstract][Full Text] [Related]
14. Serum hepatocyte growth factor activator (HGFA) in benign prostatic hyperplasia and prostate cancer.
Nagakawa O; Yamagishi T; Fujiuchi Y; Junicho A; Akashi T; Nagaike K; Fuse H
Eur Urol; 2005 Oct; 48(4):686-90. PubMed ID: 16005141
[TBL] [Abstract][Full Text] [Related]
15. Pregnancy-associated plasma protein A and extensive necrosis. Clinically significant predictors of early recurrence in stage I estrogen receptor-negative breast carcinoma.
Kuhajda FP; Eggleston JC
Lab Invest; 1985 Jul; 53(1):101-7. PubMed ID: 2409349
[TBL] [Abstract][Full Text] [Related]
16. Hormonal predictors of prostate cancer.
Sofikerim M; Eskicorapci S; Oruç O; Ozen H
Urol Int; 2007; 79(1):13-8. PubMed ID: 17627161
[TBL] [Abstract][Full Text] [Related]
17. [The significance of prostatic serum acid phosphatase as a tumor marker in prostatic cancer].
Hamami G
Hinyokika Kiyo; 1983 Oct; 29(10):1231-45. PubMed ID: 6085711
[TBL] [Abstract][Full Text] [Related]
18. Stimulation of the circulating levels of glycoprotein hormone alpha-subunit after combined administration of a luteinizing hormone-releasing hormone (LHRH) agonist and flutamide in patients with cancer of the prostate.
St-Arnaud R; Lachance R; Dupont A; Labrie F
Clin Invest Med; 1986 Nov; 9(4):215-21. PubMed ID: 2433088
[TBL] [Abstract][Full Text] [Related]
19. Insulin-like growth factor-binding protein-2 in patients with prostate carcinoma and benign prostatic hyperplasia.
Ho PJ; Baxter RC
Clin Endocrinol (Oxf); 1997 Mar; 46(3):333-42. PubMed ID: 9156044
[TBL] [Abstract][Full Text] [Related]
20. Demonstration of pregnancy-associated alpha 2-glycoprotein (alpha 2-PAG) in pregnant, estrogen-treated and breast cancer-bearing rats.
Sarcione EJ; Delluomo DS
Oncodev Biol Med; 1981; 2(5):345-54. PubMed ID: 7329816
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
